CORT
The lawsuit clock is ticking
Corcept Therapeutics is back in the awkward spotlight, and not for a shiny new drug update. Hagens Berman says investors have until April 21, 2026 to step up as lead plaintiff in a securities class action tied to allegations the company concealed repeated FDA warnings about relacorilant’s data.
The backstory is doing the heavy lifting
According to the complaint, the FDA had been waving red flags during pre-submission meetings in 2024 and 2025, warning that the data didn’t support a clean effectiveness story. But Corcept allegedly kept sounding bullish on Phase 3 readiness anyway — which is great until the agency asks for better evidence and hands you a Complete Response Letter instead.
Why investors should care
This kind of litigation doesn’t usually move a stock like a moonshot or a dumpster fire earnings print, but it can hang around like a bad sequel:
- It adds legal and reputational overhang
- It keeps attention on the FDA history around relacorilant
- It can make investors more cautious about future pipeline updates
Big picture
The core issue here isn’t just the lawsuit paperwork; it’s the reminder that biotech stories can flip fast when the regulator says, “show your work.” If Corcept wants the market to look past this, it’ll need cleaner data and fewer courtroom cameos.